Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16367302 | 0.89 | POLB (0.36) | ALDH1A1RAB9ASMN1; SMN2MAPK1ATM | |
| SCHEMBL16367343 | 0.86 | EGFR (0.36) | ALDH1A1RAB9ASMN1; SMN2MAPK1 | |
| SCHEMBL16367321 | 0.84 | ALDH1A1 (0.37) | ALDH1A1RAB9ASMN1; SMN2MAPK1ATM | |
| SCHEMBL16367340 | 0.82 | CHRM1 (0.36) | ALDH1A1RAB9ASMN1; SMN2MAPK1ATM | |
| SCHEMBL15607848 | 0.81 | PTGS2 (0.31) | — | |
| SCHEMBL16367298 | 0.81 | MAPK1 (0.35) | ALDH1A1RAB9ASMN1; SMN2MAPK1ATM | |
| SCHEMBL16367385 | 0.80 | MAPK1 (0.52) | ALDH1A1SMN1; SMN2MAPK1ATM | |
| SCHEMBL16367336 | 0.76 | L3MBTL1 (0.38) | ALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL16367310 | 0.76 | POLB (0.37) | ALDH1A1RAB9ASMN1; SMN2MAPK1ATM | |
| SCHEMBL16367349 | 0.75 | EGFR (0.37) | ALDH1A1RAB9ASMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | AUCKLAND UNISERVICES LTD (NL) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150010474-A1 | Compounds And Methods For Selective Imaging And/Or Ablation | CBR1, CBR3, BLVRB | ALDH1A1 140/4885RAB9A 4054/4885SMN1; SMN2 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.